Quick Overview: Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a ... Earn CME for related activities: Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that ... Dr. Sahil Mittal discusses his manuscript "
Hcc Whiteboard 1 The Epidemiology - Detailed Overview & Context
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a ... Earn CME for related activities: Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that ... Dr. Sahil Mittal discusses his manuscript " Drs. Mario Dicato and Eric Van Cutsem, along with Dr. Josep Tabernero, chaired the ESMO 15th World Congress on ... In this Velocity Vlog™ activity, Dr. Richard S. Finn of the UCLA Geffen School of Medicine, provides a brief overview of the ... Speaker: Hashem B. El-Serag, MD, MPH Learning Objective: Describe current and evolving global
Panelists Ghassan K. Abou-Alfa, MD; Amit G. Singal, MD; Richard Finn, MD; and Riccardo Lencioni, MD, provide insight on the ... Join Dr. Adam Burgoyne, an Associate Clinical Professor at the University of California, San Diego, and Dr. Stacey Stein, ... The ESMO World Congress on Gastrointestinal Cancer is the premier annual event in gastrointestinal cancer. At this year's ... In this talk, we discuss the challenge of confounding in Earn CME for related activities: Recent approvals in In this presentation from the Great Debates in Gastrointestinal Malignancies 2018 conference, Dr.Tanios Bekaii-Saab argues in ...
In our latest episode of Here We Stand, renowned physicians Dr. Roger Seheult and Dr. Neil Nedley explore the looming global ...
![[HR] The speech about the changing epidemiology and risk factors for HCC from Prof. Patrizia Burra](https://i.ytimg.com/vi/MI4igSJEVpw/mqdefault.jpg)
